Gallstone DiseaseNCT07453186
Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting
A study testing Diagnostic procedures in people with Gallstone Disease and Ultrasonic Diagnosis, run by Esbjerg Hospital - University Hospital of Southern Denmark at 1 site in Denmark.
Trial summary
Every year, many patients undergo weight-loss (bariatric) surgery. While this surgery leads to significant and intended weight loss, it also increases the risk of developing gallstones or other gallbladder problems. Approximately one in five patients later requires a second operation to remove the gallbladder. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Gallstone Disease, Ultrasonic Diagnosis, Bariatric Patients Undergoing Bariatric Surgery
- What is being tested?
- Diagnostic procedures
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 130 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Apr 2026to 1 Mar 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Scheduled for bariatric surgery
- Able to provide informed consent
Who cannot join
- Previous cholecystectomy
- Previous biliary surgery
- Previous liver surgery
- Inability to provide informed consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Denmark1 site, 1 recruiting
- Recruiting
Esbjerg og Grindsted Sygehus
Esbjerg, 6700
Benjamin Petersen, M.D., + 45 79 18 57 14, benjamin.drejer.petersen@rsyd.dk
About this study
Official title: Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting: Utility and Diagnostic Accuracy
Every year, many patients undergo weight-loss (bariatric) surgery. While this surgery leads to significant and intended weight loss, it also increases the risk of developing gallstones or other gallbladder problems.
Approximately one in five patients later requires a second operation to remove the gallbladder. This type of surgery carries a higher risk of complications and reoperations compared with gallbladder surgery performed in the general population.
Read more
Preventive treatment may help reduce this risk. One option is medical treatment with Ursochol, which has been shown to lower the risk of developing gallstones after bariatric surgery. However, this treatment is only effective in patients who have not already developed gallstones before surgery.
This means patients need a reliable preoperative ultrasound examination of the gallbladder. Unfortunately, performing ultrasound can be technically challenging in patients with obesity, making it harder to detect small stones or other abnormalities.
The goal is therefore to improve the examination of the gallbladder in patients undergoing bariatric surgery in order to better identify who may benefit from preventive treatment.
The study
The investigators are comparing two types of ultrasound examination of the gallbladder:
- Standard ultrasound performed on the outside of the abdomen using a handheld probe.
- Laparoscopic ultrasound performed during bariatric surgery using a small ultrasound probe placed inside the abdomen, typically placed on the liver near the gallbladder.
It is of interest to find out whether the ultrasound performed during surgery finds more:
- Gallstones
- Sludge
- Small stones (microlithiasis)
- Thickening of the gallbladder wall
By improving detection, the investigators aim to better guide preventive treatment and reduce the need for future gallbladder surgery.
Read the detailed description
- TITLE Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting
- BACKGROUND AND RATIONALE 2.1 Clinical Background Bariatric surgery is an established and effective treatment for severe obesity. In Denmark, approximately 2,000 bariatric procedures are performed annually. These procedures result in significant and intended weight loss and improvement in metabolic comorbidities. However, rapid weight loss is associated with an increased risk of gallstone formation. Gallstone disease is one of the most common postoperative complications following bariatric surgery. Approximately 10% of patients undergo cholecystectomy within two years after surgery, increasing to up to 20% within ten years. Importantly, cholecystectomy in patients who previously underwent bariatric surgery is associated with:
- Increased risk of surgical complications
- Higher rates of reoperation
- More technically complex procedures
- Increased risk of bile duct injury In patients with Roux-en-Y gastric bypass, management of biliary tract disease is particularly challenging due to altered gastrointestinal anatomy, which complicates endoscopic access (e.g., ERCP). 2.2 Preventive Treatment and Diagnostic Challenge Prophylactic treatment with ursodeoxycholic acid (Ursochol) has been shown to significantly reduce the risk of symptomatic gallstone disease in the first two years after bariatric surgery. However:
- Ursochol is only effective in patients who do not already have gallstones.
- Therefore, accurate preoperative detection of gallstones is essential. Conventional transabdominal ultrasound (TAUS) is the standard imaging modality for gallbladder evaluation. However, in patients with severe obesity:
- Ultrasound penetration is limited
- Image quality may be reduced
- Small stones and sludge may be overlooked
- Sensitivity may be as low as 62-68% Thus, diagnostic uncertainty may lead to:
- Under-treatment (missed stones)
- Over-treatment (inappropriate prophylaxis)
- Inconsistent national implementation 2.3 Rationale for Laparoscopic Ultrasound (LUS) Laparoscopic ultrasound (LUS) allows:
- Direct placement of the probe on the liver surface
- Shorter acoustic distance
- Higher image resolution
- Potentially improved detection of subtle pathology
- Fewer hospital visits for the patients prior to surgery Only one prior study has directly compared TAUS and LUS in this population. That study suggested higher overall pathology detection with LUS, but lacked:
- Histological confirmation
- Sample size justification
- Assessment of microlithiasis
- Gallbladder wall measurements
- Formal evaluation of interobserver agreement within each ultrasound modality Therefore, a well-designed prospective paired diagnostic study is warranted.
- OBJECTIVES
3.1 Primary Objective To compare the diagnostic detection rate of gallbladder pathology between transabdominal ultrasound (TAUS) and laparoscopic ultrasound (LUS) in patients undergoing bariatric surgery.
3.2 Secondary Objectives
- To evaluate interobserver agreement within TAUS and LUS examinations
- To compare examination time between modalities
- To assess image quality
- HYPOTHESES
- Laparoscopic ultrasound detects significantly more gallbladder pathology than transabdominal ultrasound.
- LUS has lower interobserver variability compared to TAUS.
- STUDY DESIGN Prospective observational diagnostic comparative study with paired within-patient design.
Each participant undergoes:
- Two independent TAUS examinations
- Two independent LUS examinations
All examinations are performed blinded and independently.
No randomization is performed.
No experimental interventions are introduced.
- STUDY PROCEDURES
6.1 Preoperative Phase
Participants undergo:
- Two transabdominal ultrasounds
- Performed on the same day
- By two independent radiologists/sonographers
- Blinded to each other's findings
6.2 Intraoperative Phase
During planned bariatric surgery:
- Two surgeons independently perform laparoscopic ultrasound
- Probe placed directly on liver surface
- Examinations blinded
- Adds 5-10 minutes to procedure
- STATISTICAL ANALYSIS PLAN
7.1 Primary Analysis McNemar's test for paired binary outcomes.
Significance level: 0.05 (one-sided)
Power: 90%
7.2 Sample Size Calculation Sample size was calculated for a paired binary comparison of the composite gallbladder pathology outcome between transabdominal ultrasound (TAUS) and laparoscopic ultrasound (LUS) using a one-sided McNemar test (α=0.05, power=90%). The sample size was calculated in two ways. Under one model, we assumed the detection rates of 25% for TAUS and 35% for LUS with an estimated between-modality correlation of 0.70. In the second model, we assumed discordant proportions of 0.10 (TAUSnegative / LUSpositive) and 0.01 (TAUSpositive / LUSnegative). Approximately in both models, the required sample size was 117 evaluable paired patients; allowing for 10% dropout/non-evaluable cases, we will enroll 130 patients in total.
7.3 Secondary Analyses • Interobserver agreement: Cohen's kappa
- Subgroup analyses (BMI strata, bariatric surgery)
All analyses conducted in STATA.
- ETHICAL CONSIDERATIONS
8.1 Risk Assessment Both TAUS and LUS examinations are well known diagnostic modalities without any known risk profile. The LUS procedure will add 5-10 minutes of additional surgery, which seems reasonable.
Overall, the risk of the examinations are considered minimal.
8.2 Potential Benefits • Improved diagnostic precision
- Better patient selection for preventive treatment
- Reduced need for future gallbladder surgery
- Simpler ultrasound examinations
- DATA MANAGEMENT
- Data stored in secure SharePoint research environment and REDCap Systems
- GDPR compliant
- Restricted access
- Registered internally at hospital
- DISSEMINATION
Results will be:
- Published regardless of outcome
- Submitted to peer-reviewed journals
- FUNDING
- Part of a PhD program
- No funding from private companies
- Additional funding sought from regional and national foundations
- EXPECTED IMPACT
If LUS demonstrates superior diagnostic performance:
- It may guide selective prophylactic therapy
- It may reduce long-term gallbladder morbidity
- It may standardize diagnostic workup
This study has direct translational relevance to clinical practice.
- Being tested
- Diagnostic procedures
- Keywords
- Bariatric surgery, Gallstone disease, Metabolic surgery, Biliary disease, Ultrasound, Laparoscopic ultrasound
- Medical subject headings
- Cholelithiasis, Gallbladder Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Diagnostic proceduresDiagnostic test
Also called Transabdominal ultrasound, Laparoscopic ultrasound
In the same patients, we will do both transabdominal and laparoscopic ultrasound
| Study group | Role | What they receive |
|---|---|---|
| Ultrasound examination | Other | Not described Receives: Diagnostic Test: Diagnostic procedures |
What is being measured
The primary outcome is the main question the study is designed to answer.
Gallbladder pathology (yes / no)
Composite endpoint consisting of gallstones (yes/no), slugde (yes/no), micro- lithiasis (yes/no), diffuse gallbladder wall thickness over 3 mm (yes/no).
Measured: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery
Secondary outcomes (1)
Interobserver variability
Interobserver agreement (Cohen's kappa)
Measured: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Mar 2026
- Study start1 Apr 2026
- Primary completion1 Jun 2028 (estimated)
- Study completion1 Mar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Gallstone DiseaseStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Prospective observational diagnostic accuracy study with paired design.
- Masking
- None (open label)
- Enrolment
- 130 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Esbjerg Hospital - University Hospital of Southern Denmark
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Benjamin Drejer Petersen, Esbjerg Hospital - University Hospital of Southern Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07453186
- Sponsor's protocol ID
- EsbjergH
- Status last verified
- May 2026
- First submitted
- 25 Feb 2026
- Last updated
- 2 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Individual participant data will not be shared due to national data protection regulations and institutional restrictions.
Study at a glance
From the registry record, last updated by the sponsor on 2 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting: Utility and Diagnostic Accuracy
- ClinicalTrials.gov ID
- NCT07453186
- Acronym / sponsor ID
- EsbjergH
- Keywords
- Bariatric surgery, Gallstone disease, Metabolic surgery, Biliary disease, Ultrasound, Laparoscopic ultrasound
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 130 participants (estimated)
- Lead sponsor
- Esbjerg Hospital - University Hospital of Southern DenmarkUniversity, hospital or other
- Study start
- 1 Apr 2026 (actual)
- Primary completion
- 1 Jun 2028 (estimated)
- Study completion
- 1 Mar 2029 (estimated)
- First posted
- 5 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Every year, many patients undergo weight-loss (bariatric) surgery. While this surgery leads to significant and intended weight loss, it also increases the risk of developing gallstones or other gallbladder problems.
Approximately one in five patients later requires a second operation to remove the gallbladder. This type of surgery carries a higher risk of complications and reoperations compared with gallbladder surgery performed in the general population.
Preventive treatment may help reduce this risk. One option is medical treatment with Ursochol, which has been shown to lower the risk of developing gallstones after bariatric surgery. However, this treatment is only effective in patients who have not already developed gallstones before surgery.
This means patients need a reliable preoperative ultrasound examination of the gallbladder. Unfortunately, performing ultrasound can be technically challenging in patients with obesity, making it harder to detect small stones or other abnormalities.
The goal is therefore to improve the examination of the gallbladder in patients undergoing bariatric surgery in order to better identify who may benefit from preventive treatment.
The study
The investigators are comparing two types of ultrasound examination of the gallbladder:
- Standard ultrasound performed on the outside of the abdomen using a handheld probe.
- Laparoscopic ultrasound performed during bariatric surgery using a small ultrasound probe placed inside the abdomen, typically placed on the liver near the gallbladder.
It is of interest to find out whether the ultrasound performed during surgery finds more:
- Gallstones
- Sludge
- Small stones (microlithiasis)
- Thickening of the gallbladder wall
By improving detection, the investigators aim to better guide preventive treatment and reduce the need for future gallbladder surgery.
Detailed description
- TITLE Transabdominal and Laparoscopic Ultrasound in a Bariatric Setting
- BACKGROUND AND RATIONALE 2.1 Clinical Background Bariatric surgery is an established and effective treatment for severe obesity. In Denmark, approximately 2,000 bariatric procedures are performed annually. These procedures result in significant and intended weight loss and improvement in metabolic comorbidities. However, rapid weight loss is associated with an increased risk of gallstone formation. Gallstone disease is one of the most common postoperative complications following bariatric surgery. Approximately 10% of patients undergo cholecystectomy within two years after surgery, increasing to up to 20% within ten years. Importantly, cholecystectomy in patients who previously underwent bariatric surgery is associated with:
- Increased risk of surgical complications
- Higher rates of reoperation
- More technically complex procedures
- Increased risk of bile duct injury In patients with Roux-en-Y gastric bypass, management of biliary tract disease is particularly challenging due to altered gastrointestinal anatomy, which complicates endoscopic access (e.g., ERCP). 2.2 Preventive Treatment and Diagnostic Challenge Prophylactic treatment with ursodeoxycholic acid (Ursochol) has been shown to significantly reduce the risk of symptomatic gallstone disease in the first two years after bariatric surgery. However:
- Ursochol is only effective in patients who do not already have gallstones.
- Therefore, accurate preoperative detection of gallstones is essential. Conventional transabdominal ultrasound (TAUS) is the standard imaging modality for gallbladder evaluation. However, in patients with severe obesity:
- Ultrasound penetration is limited
- Image quality may be reduced
- Small stones and sludge may be overlooked
- Sensitivity may be as low as 62-68% Thus, diagnostic uncertainty may lead to:
- Under-treatment (missed stones)
- Over-treatment (inappropriate prophylaxis)
- Inconsistent national implementation 2.3 Rationale for Laparoscopic Ultrasound (LUS) Laparoscopic ultrasound (LUS) allows:
- Direct placement of the probe on the liver surface
- Shorter acoustic distance
- Higher image resolution
- Potentially improved detection of subtle pathology
- Fewer hospital visits for the patients prior to surgery Only one prior study has directly compared TAUS and LUS in this population. That study suggested higher overall pathology detection with LUS, but lacked:
- Histological confirmation
- Sample size justification
- Assessment of microlithiasis
- Gallbladder wall measurements
- Formal evaluation of interobserver agreement within each ultrasound modality Therefore, a well-designed prospective paired diagnostic study is warranted.
- OBJECTIVES
3.1 Primary Objective To compare the diagnostic detection rate of gallbladder pathology between transabdominal ultrasound (TAUS) and laparoscopic ultrasound (LUS) in patients undergoing bariatric surgery.
3.2 Secondary Objectives
- To evaluate interobserver agreement within TAUS and LUS examinations
- To compare examination time between modalities
- To assess image quality
- HYPOTHESES
- Laparoscopic ultrasound detects significantly more gallbladder pathology than transabdominal ultrasound.
- LUS has lower interobserver variability compared to TAUS.
- STUDY DESIGN Prospective observational diagnostic comparative study with paired within-patient design.
Each participant undergoes:
- Two independent TAUS examinations
- Two independent LUS examinations
All examinations are performed blinded and independently.
No randomization is performed.
No experimental interventions are introduced.
- STUDY PROCEDURES
6.1 Preoperative Phase
Participants undergo:
- Two transabdominal ultrasounds
- Performed on the same day
- By two independent radiologists/sonographers
- Blinded to each other's findings
6.2 Intraoperative Phase
During planned bariatric surgery:
- Two surgeons independently perform laparoscopic ultrasound
- Probe placed directly on liver surface
- Examinations blinded
- Adds 5-10 minutes to procedure
- STATISTICAL ANALYSIS PLAN
7.1 Primary Analysis McNemar's test for paired binary outcomes.
Significance level: 0.05 (one-sided)
Power: 90%
7.2 Sample Size Calculation Sample size was calculated for a paired binary comparison of the composite gallbladder pathology outcome between transabdominal ultrasound (TAUS) and laparoscopic ultrasound (LUS) using a one-sided McNemar test (α=0.05, power=90%). The sample size was calculated in two ways. Under one model, we assumed the detection rates of 25% for TAUS and 35% for LUS with an estimated between-modality correlation of 0.70. In the second model, we assumed discordant proportions of 0.10 (TAUSnegative / LUSpositive) and 0.01 (TAUSpositive / LUSnegative). Approximately in both models, the required sample size was 117 evaluable paired patients; allowing for 10% dropout/non-evaluable cases, we will enroll 130 patients in total.
7.3 Secondary Analyses • Interobserver agreement: Cohen's kappa
- Subgroup analyses (BMI strata, bariatric surgery)
All analyses conducted in STATA.
- ETHICAL CONSIDERATIONS
8.1 Risk Assessment Both TAUS and LUS examinations are well known diagnostic modalities without any known risk profile. The LUS procedure will add 5-10 minutes of additional surgery, which seems reasonable.
Overall, the risk of the examinations are considered minimal.
8.2 Potential Benefits • Improved diagnostic precision
- Better patient selection for preventive treatment
- Reduced need for future gallbladder surgery
- Simpler ultrasound examinations
- DATA MANAGEMENT
- Data stored in secure SharePoint research environment and REDCap Systems
- GDPR compliant
- Restricted access
- Registered internally at hospital
- DISSEMINATION
Results will be:
- Published regardless of outcome
- Submitted to peer-reviewed journals
- FUNDING
- Part of a PhD program
- No funding from private companies
- Additional funding sought from regional and national foundations
- EXPECTED IMPACT
If LUS demonstrates superior diagnostic performance:
- It may guide selective prophylactic therapy
- It may reduce long-term gallbladder morbidity
- It may standardize diagnostic workup
This study has direct translational relevance to clinical practice.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Prospective observational diagnostic accuracy study with paired design.
| Arm | Type | Receives |
|---|---|---|
| Ultrasound examination | Other | Diagnostic Test: Diagnostic procedures |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age ≥18 years
- Scheduled for bariatric surgery
- Able to provide informed consent
Key exclusion criteria (4 listed)
- Previous cholecystectomy
- Previous biliary surgery
- Previous liver surgery
- Inability to provide informed consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Diagnostic proceduresAlso: Transabdominal ultrasound, Laparoscopic ultrasoundIn the same patients, we will do both transabdominal and laparoscopic ultrasound | Diagnostic test | Ultrasound examination |
Primary outcome
Gallbladder pathology (yes / no)
Time frame: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery
Composite endpoint consisting of gallstones (yes/no), slugde (yes/no), micro- lithiasis (yes/no), diffuse gallbladder wall thickness over 3 mm (yes/no).
1 secondary outcome
Interobserver variability
Time frame: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jun 2026.
- Individual participant dataSharing planned: No. Individual participant data will not be shared due to national data protection regulations and institutional restrictions.
Related trials for Gallstone Disease
Recruiting
Surgical Techniques: Robotic Versus Conventional Laparoscopic Cholecystectomy IN Benign Gallbladder Disease
Cholecystectomy, Robotic, Cholecystectomy, Laparoscopic
Not yet recruitingObservational study
ABCG8, UGT1A1 and Gallstone Disease After Bariatric Surgery
Gallstone Disease, Bariatric Surgery
RecruitingObservational study
Gut Microbiome and Metabolome in Patients With Gallstone Disease After Surgical and Endoscopic Interventions
Gallstone Disease, Bile Duct Diseases
RecruitingPhase 1
Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Trimedat® 100 mg Tablets in Healthy Volunteers.
Irritable Bowel Syndrome, Gallstone Disease
RecruitingObservational study
EULAT Eradicate GBC
Gallbladder Cancer, Gallstone Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Diagnostic procedures in people with Gallstone Disease and Ultrasonic Diagnosis, run by Esbjerg Hospital - University Hospital of Southern Denmark at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Benjamin Petersen, M.D. (+45 79 18 57 14, benjamin.drejer.petersen@rsyd.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Gallbladder pathology (yes / no) (time frame: From preoperative ultrasound (within 31 days before surgery) to laparoscopic ultrasound during bariatric surgery). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jun 2026; AzTrials last refreshed its copy on 7 Nov 2026.